Introduction: Participation in early-phase HIV cure studies includes clinical risks with little to no likelihood of clinical benefit. Examining the willingness of people living with HIV to participate is important to guide study design and informed consent. Our study examined the overall willingness of people living with HIV to participate in HIV cure research in the US, focusing on perceived risks and benefits of participation. Methods: We undertook an online survey of adults living with HIV in the US. Survey questions were developed based on previous research and a scoping review of the literature. We quantitatively assessed individuals' perceived risks and benefits of HIV cure-related research and respondents' willingness to participate in different modalities of HIV cure studies. Results: We recruited 409 study participants of whom 400 were eligible for the study and were included in the analysis (nine were not eligible due to self-declared HIV-negative status). We found >50% willingness to participate in 14 different types of HIV cure studies. Perceived clinical benefits and social benefits were important motivators, while personal clinical risks appeared to deter potential participation. Roughly two-thirds of survey respondents (68%) indicated that they were somewhat willing to stop treatment as part of HIV cure research. In the bivariate models, females, African Americans/blacks, Hispanics, individuals in the lowest income bracket, people living with HIV for longer periods of their lives, and people who were self-perceived 'very healthy' were less willing to participate in certain types of HIV cure studies than others. Multivariate results showed the perceived benefits (adjusted odds ratios >1) and perceived risks (adjusted odds ratios <1) acted as potential motivators and deterrents to participation, respectively. Conclusion: Our study is the first attempt to quantify potential motivators and deterrents of participation in HIV cure research in the US using perceived risks and benefits. The results offer guidance to HIV cure researchers and developers of interventions about the beneficial and detrimental characteristics of HIV cure strategies that are most meaningful to people living with HIV. The study also highlights new potential lines of inquiry for further social science and ethics research.
Introduction
The case of one individual, Timothy Ray Brown, thought to be cured of HIV, has inspired renewed scientific interest and investment in discovering an HIV cure, either one that eradicates the HIV reservoir, or one that induces mechanisms that result in durable viral suppression [1] . While researchers, bioethicists and regulators are attempting to minimise the risk to study participants, they must also balance the need to demonstrate that the intervention has the intended effect. As such, HIV cure research efforts carry great risks [2] [3] [4] , including the need to withdraw antiretroviral therapy (ART) in order to prove whether a cure intervention has had its intended effect.
To date, little data are available on willingness of people living with HIV to participate in HIV cure studies. Although a few studies have explored perceptions of HIV cure research [5] [6] [7] , none have focused systematically on perceived risks and benefits of study participation. Such studies could allow for a more informed a priori process for intervention candidate selection, study design, and methods by which prospective participants are recruited, screened and informed about clinical research. This study reports results from a survey that explored individuals' perceived risks and benefits of participation in HIV cure research in the US.
Methods
We administered an online, cross-sectional survey in autumn 2015 using Qualtrics software (Provo, Utah). We recruited study participants via a convenience sample of people living with HIV using established treatment and cure research listservs, including those for immune-based therapy (IBT), the Martin Delaney Collaboratories Community Advisory Board (MDC CAB), the AIDS Clinical Trials Group (ACTG), the AIDS Treatment Activists Coalition (ATAC) and others.
Inclusion criteria for survey participation were:
• Persons self-reported to be living with HIV • Willingness to answer survey questions • ≥18 years of age • Living in the US or its territories • Ability to read/write in English • Willingness to provide informed consent.
The recruitment method included a reference to contributing to a study on willingness to participate in HIV cure research. People could participate regardless of whether they were on ART. We focused on the US because of the growing momentum for HIV cure research in the country and increased investment in an already sophisticated research infrastructure with the capacity to undertake HIV cure clinical research.
The survey questions were developed by previous work in the field and our scoping review of the literature focused on risks and benefits of study participation [8] . We pilot tested the survey and vetted key terms and definitions with the members of HIV cure research community advisory boards. The Institutional Review Board (IRB) of the University of North Carolina at Chapel Hill approved the study and participants provided consent online.
Measures
The survey covered demographic characteristics, health status and perceptions, history with, and general interest in HIV cure-related research. Respondents reported yes/no/don't know about willingness to participate in each of the 14 types of HIV curerelated studies (listed in Figure 1 ). These correspond to the types of HIV cure studies most likely to enrol study participants in the coming years per our review of the literature (8) . HIV cure study types were constructed as dichotomous variables by excluding all 'don't know' or incomplete responses. Additionally, using 5-point Likert scales, we asked survey respondents to rate 21 potential benefits and 35 potential risks in terms of how likely each one might motivate/discourage them from participation in studies. Given the distributions, the extreme answer (e.g. 'very important') was given a value of 1 and all other, lower levels of importance given a value of 0. We provided definitions of complex words in lay terms and used the survey as an educational opportunity for respondents. Figure 1 displays how the various study types were defined.
Statistical analysis
We ran bivariate correlation tests between each individual-level characteristic and willingness to participate in 14 HIV cure study types, reporting Fisher's exact tests and odds ratios.
Using multivariate analysis, we examined the relationships between perceptions of potential benefits and potential risks and willingness to participate in five specific HIV cure study types with high risk interventions: (1) latency-reversing agents; (2) allogeneic stem cell transplants; (3) autologous stem cell transplants; (4) therapeutic vaccines; and (5) antibodies or molecules. For each of the five HIV cure study types, we estimated separate logistic regression models for each perception of potential benefit as a motivator or potential risk as a deterrent as the key independent variable, controlling for demographics and health status characteristics. Because this is an exploratory analysis, and not testing any single specific hypothesis, we did not make any adjustments for multiple testing; rather, we present all results and associated P-values. All data analyses were conducted using Stata (version 11).
Results

Demographics
Of the 400 eligible participants (nine were not eligible due to self-declared HIV-negative status), representing 38 states and Puerto Rico, 343 respondents completed the survey by answering all questions and 57 partially completed the survey. Respondents were 78% men and ranged in ages between 19 and 74 years of age (median age 51). The sample was ethnically diverse: 65% Caucasians/whites, 17% African Americans/black, 12% Hispanic/ Hispanic descent and 4% mixed race. Virtually all survey respondents had at least a high school degree or equivalent and nearly half had a 4-year degree or higher. More than one-third (37%) of survey respondents earned less than $25,000 annually and another third (35%) earned more than $50,000 (Table 1) .
Willingness to participate in HIV cure-related studies Figure 1 shows the hierarchy of the 14 different kinds of HIV cure-related studies that potential participants indicated they would be willing to join. There was a near universal willingness to participate in surveys, interviews, focus groups and basic blood draw studies (between 85% and 97%). For the other types of studies, willingness to participate ranged between 52% and 78%. Figure 2 disaggregates the data by sex/gender.
Perceptions of potential benefits
Perceived clinical benefits or social benefits appeared to be more important motivators than personal benefits ( Figure 3) . Feeling good about contributing to HIV cure research was the most popular perceived personal benefit, and social benefits of helping find a cure for HIV; helping other people with HIV in the future; and contributing to scientific knowledge were three of the four highest ranked perceived benefits overall. Potential participants valued gaining knowledge about their health (78%), hoped their health would improve (73%), desired to improve their immune system (92%) and to reduce their HIV reservoir (85%). Figure 4 disaggregates these data by sex/gender.
Perceptions of potential risks and burdens
Personal clinical risks appeared to be more likely to deter potential participation than personal risks or burdens or potential social risks ( Figure 5 ). Risks were defined as potential harms or complications, while burdens included drawbacks of participation such as intensive time commitments and discomforts. Activation of genes that could cause cancer (49%) and the possibility of developing resistance to HIV treatment (37%) were the most prevalent perceived deterrents. Spinal tap (26%) and bone marrow biopsies (22%) were the least acceptable study procedures. Hair loss was a stronger possible deterrent than more immediate symptoms/side effects, such as vomiting, pain, headache, or nausea. Finally, the risk of transmitting HIV to others (in the case of an unsuspected viral rebound) was a real possible social deterrent. Figure 6 disaggregates these data by sex/gender. Leukaphereses and aphereses were defined as 'laboratory procedures where selected immune cells are separated out from the blood and the rest of the blood is returned to the veins'. Therapeutic vaccines were defined as 'vaccines that control disease in people already infected rather than vaccines that prevent infection'. Phase II or III studies were defined as safety and efficacy studies. Use of unique antibodies or molecules was defined as using, for example, a protein that has a dual function. Autologous transplants of stem cells were defined as 'studies involving transplantation of your (autologous) stem cells'. First-in-human studies were defined as 'studies that involve totally new treatments or approaches'. Intensification of treatment was defined as 'studies that involve taking more than 3 different classes of drugs at the same time'. Latency reversing agents were defined as 'studies that involve agents that could reactivate HIV that has become dormant inside the cells'. Allogeneic transplants of stem cells were defined as 'studies that involve a transplantation of someone else's (allogeneic) stem cells' Figure 2 . Difference between female and male willingness to consider participating in HIV cure-related studies in the US, 2015. Transgender women are included in the Females category; P-values reflect the chi-squared test result for differences between females and males in answering 'Yes'. *** Statistically significant at 0.1% level; ** statistically significant at 1% level; * statistically significant at 5% level their peers in higher income brackets. Furthermore, individuals in poorer health were considerably more willing to participate in studies involving latency-reversing agents and allogeneic stem cell transplants than healthier people. Recently diagnosed individuals were nearly two to three times more willing to participate in studies than people who had lived with the virus for a larger proportion of their lives across seven of the ten interventional HIV cure study types.
Multivariate results: association of willingness to participate (WTP) in HIV cure studies and the self-assessed importance of potential benefits/risks as motivators/deterrents to participating
Multivariate results are shown in Tables 2 and 3 . The summary results for the perceptions of the 21 potential benefits as very important motivators to participation are summarised in Table 2 . The summary results for the perceptions of the 35 potential risks as very likely deterrents to participation can be found in Table 3 . All models control for gender, age, ethnicity, education, income, region, health status, being in control of own healthcare, percentage of life lived with HIV, ever volunteered for HIV treatment study, ever volunteered for HIV cure study and general interest in HIV cure studies.
Perceptions of benefits (Table 2) were positively correlated with willingness to participate. Respondents who rated feeling good about contributing to HIV cure research as a very important motivator had higher odds of being willing to participate in allogeneic stem cell transplant studies, autologous stem cell transplant studies, therapeutic vaccine studies and in antibody studies. The perception that helping find a cure for HIV as a very important motivator was associated with 12 times the odds of being willing to participate in allogeneic stem cell transplant studies.
Perceptions of risks (Table 3) were negatively correlated with willingness to participate. In particular, perceptions that the potential personal clinical risks, as well as potential risk of pain or discomfort from study procedures (spinal tap, bone marrow biopsies, rectal biopsies, isolation of white blood cells) were more significant in magnitude than other types of risks, symptoms (except for nausea), burdens, and potential social risks. Moreover, a small number of survey respondents found the risk factors very likely to discourage them from participating ( Figure 5 ), generally overlapping with those who were not willing to participate in any of the study types, partly explaining the strong associations.
Discussion
Our findings provide a unique perspective into willingness of individuals living with HIV in the US to participate in HIV curerelated studies, focusing on perceptions of risks and benefits. More than 50% of survey respondents indicated that they would be willing to participate in all types of HIV cure-related studies. The high apparent willingness to participate in HIV cure research and the belief that a cure for HIV was already available by a minority of respondents underscores the need to better educate potential study candidates about the different types of HIV cure studies and their potential risks in order to prevent therapeutic or curative misconception [9] . Our study extends the literature in several ways, in that, although willingness to participate may not correlate with actual participation, the study shows there is a strong level of willingness to participate in HIV cure research in a diverse population of people living with HIV in the US. Furthermore, this was the first attempt to quantify motivation and deterrence of participation in HIV cure-related studies using perceived risks and benefits. The results offer guidance to HIV cure researchers and developers of interventions about the beneficial and detrimental characteristics of HIV cure strategies that are most meaningful to people living with HIV. The study also revealed differences in motivation across HIV cure study types and differences by gender, ethnicity and perceived health status that may be actionable as part of research recruitment efforts.
Descriptive results revealed potential misperceptions about clinical benefits. While people may be willing to participate in HIV cure research, they may be largely unaware of the potential risks and lack of direct clinical benefits in early HIV cure research and this has ethical implications for informed consent. For example, people living with HIV may expect to gain knowledge about their health but HIV cure research results are most often compiled and published in the aggregate and not returned to study participants.
Hope that health will improve was also a strong motivator factor, yet there is a real possibility of individual harm while advancing scientific HIV cure knowledge. Reducing the HIV reservoir was perceived as a clinical benefit by potential participants, although a reservoir decrease may not confer direct clinical benefit. Thus, HIV cure research implementers need to be careful how knowledge of results, risk of harms, lack of direct clinical benefits and reservoir reductions are discussed in informed consent forms to avoid misperceptions around clinical benefits (or lack thereof). True informed consent and knowledge around clinical risks should be assured using tests of understanding in order to avoid underestimating risks and overestimating expectations for personal benefits. Furthermore, the risk of transmitting HIV to others (in the case of an unsuspected viral rebound) was a real possible demotivator (28% very likely to be discouraged). This result was reminiscent of similar prior surveys that showed the importance placed on reducing HIV transmission risk [6, 10] .
Although early HIV cure studies confer little to no clinical benefit [3, 11] , it is possible that study participants still perceive the likelihood of benefits when deciding to join studies, either through therapeutic misconception or other tendencies to overstate the potential for benefits whilst simultaneously discounting potential risks to self. Our findings also demonstrated the importance of not underestimating the contribution of emotional and psychological benefits in HIV cure research participation in general. The highest rated social and personal benefits were most often psychological in nature, consistent with similar studies from the HIV prevention and treatment literature [12, 13] . HIV cure scientists should appreciate the perceived intangible benefits to participation and seriously consider the altruistic appeal to scientific advancement when conducting recruitment efforts, while emphasising the lack of direct medical benefits.
We found that 68% of potential HIV cure research participants indicated they were very willing or somewhat willing to interrupt treatment as part of HIV cure research, consistent with a previously published US survey [7] . The finding is important because HIV treatment interruptions may become more prevalent as investigational HIV cure strategies start showing signals of potential efficacy.
Limitations
Several limitations of the study should be acknowledged. Hair loss (n=358) VomiƟng (n=358) Pre-defined, controlled discomfort or pain (n=356)
Headache ( and it remains to be seen whether potential volunteers would participate if the opportunity arises. While results should not be used to predict enrolment rates, responses can inform study designs, including understanding of risks and benefits and considerations for informed consent and recruitment efforts. Study participants may have had limited knowledge of the inherent risks of each HIV cure study type, and if they knew more about them their responses might change. While the high level of willingness to participate is encouraging, previous research in HIV and other diseases suggests that stated willingness will not translate into actual research participation to the same degree and we suspect social desirability bias. Second, the sample may have been biased to those who had access to HIV cure/treatment listservs and the internet. As such, the sample was not representative of the overall population of people living with HIV in the US (median age 51). Individuals without internet access, non-English speakers and minors were excluded. Yet, the sample had proportionally more females and was ethnically more diverse than a previous US survey on willingness to participate in HIV cure studies [7] . Third, referencing HIV cure research as part of the survey recruitment may have biased the sample towards those with an interest in finding a cure. Fourth, the complexity of the survey wording may have limited full understanding of items, although we mitigated this risk by providing definitions of key concepts in lay terms throughout the survey instrument.
Possible avenues for future research
Given the great risks involved in HIV cure research, we will need to better understand the role of altruism in high-risk/low-benefit studies. We will also need to better understand the factors that affect participation in specific types of HIV cure studies and assess potential participants' knowledge and understanding of the various cure research modalities. Table 4 summarises potential future study questions around HIV cure research participation. Social science research can help guide meaningful community and stakeholder engagement, enhance patient-participant and clinician-researcher communications and contribute to more successful clinical studies.
Moving forward, it is essential that we pursue HIV cure-related research in a way that places the needs and perspectives of people living with HIV at the centre of research. Human studies in HIV cure are part of a growing field that raises several complex implementation challenges as well as ethical issues related to participation. Understanding perceptions of risks and benefits of HIV cure research participation and factors that affect decisions to participate can, thus, help inform study design and the development of ethical informed consent procedures, enhance recruitment efforts and contribute to researcher-community collaboration towards finding a cure. Table 2 . Odds ratios of willingness to participate in particular types of HIV cure-related studies based on perception that a potential benefit is a 'Very Important' motivating factor to participating in the US, 2015
Key independent (benefit) Each benefit variable was included in a separate model with the control variables: gender, age, ethnicity, education, income, region, health status, being in control of own healthcare, percentage of life lived with HIV, ever volunteered for HIV treatment study, ever volunteered for HIV cure study and general interest in HIV cure studies (except when omitted for perfect collinearity). Odd ratios on the control variables are not displayed. *** Statistically significant at the 0.1% level; ** statistically significant at the 1% level; * statistically significant at the 5% level. Robust standard errors estimated. Table 3 . Odds ratios of willingness to participate in particular types of HIV cure-related studies based on perception that a potential risk is 'Very likely to discourage' participation in studies in the US, 2015
Key independent (risk) How can we increase recruitment of women and under-represented groups in HIV cure studies?
Would asking for long-term follow-up of study participants negatively affect overall recruitment or would long-term follow-up make study participants feel better?
How can we begin to study therapeutic (or curative) misconception in HIV cure research?
What motivations to join HIV cure studies are ethically questionable?
How does long-term survival with HIV affect willingness to participate and actual participation in HIV cure research?
What factors affect willingness to participate in studies that include treatment interruption?
Research with actual study participants
Would collaboration from biomedical HIV cure scientists, either retrospectively or prospectively as part of actual HIV cure studies (e.g. nested social sciences research), be required? What does HIV cure research mean for quality of life outcomes (such as Short-Form-36 Health Survey)?
What factors predict retention (or serial participation) in HIV cure studies?
Research with study decliners (more difficult)
What are some of the reasons that cause people living with HIV to decline participation in HIV cure research?
Research with clinician-researchers and policy-makers
How do clinician-researchers and policymakers view risks in HIV cure research?
Research ethics questions
What is an acceptable risk-benefit balance for potential HIV cure study participants?
Are there groups who are more vulnerable than others in HIV cure research?
How can HIV cure researchers best measure effective management of scientific uncertainty?
ORIGINAL Household income $25k-$50k group = 3.6 × WTP of <$25k group $25k-$50k = 3.8 × WTP and $100k-$125k 
